SEC Tracker
Get the app

Ardelyx ARDX

Ardelyx reported a net loss of $737,000 for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $127.66 million for the three months ended Sep 30, 2026.
  2. Net loss of $737,000 for the three months ended Sep 30, 2026.
  3. Cash and equivalents of $46.32 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Ardelyx files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes condensed balance sheets, statements of operations, and changes in stockholders' equity.
  2. It shows total assets of $587,525 thousand as of September 30, 2026.
  3. The company reported revenue of $127,655 thousand for the three months ended September 30, 2026.
  4. This includes product sales, licensing, and royalty revenue.
  5. The net loss for the period was $737 thousand.
  6. The company's balance sheet shows cash and cash equivalents of $46,317 thousand as of September 30, 2026.
  7. Total liabilities were $423,479 thousand as of the same date.

7 of 8 claims matched the filing text.

Not found in the filing text

  • In its 10-Q for the quarter ended September 30, 2026, ARDELYX, INC. reported revenue of $127.7 million.

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • This represents a 15.7% increase from the same period in the prior year.

From the filing

Item 1. Financial statements

ITEM 1.1 1FINANCIAL STATEMENTS1 ARDELYX, INC.

CONDENSED BALANCE SHEETS1

(Unaudited) (in thousands, except share and per share amounts)
September 30, 2026December 31, 2025
Assets
Current assets
Cash and cash equivalents6$46,3176$67,999
Short-term investments239,021196,690
Accounts receivable93,44171,848
Inventory24,44017,735
Prepaid commercial manufacturing17,16114,479
Prepaid expenses and other current assets21,00813,566
Total current assets441,388382,317
Property and equipment, net1,5702,184
Inventory, non-current133,119105,372
Right-of-use assets3,6924,795
Other assets7,7566,936
Total assets2$587,5252$501,604
Liabilities and stockholders' equity
Current liabilities
Accounts payable$33,657$19,235
Accrued compensation and benefits17,59219,108
Current portion of operating lease liability1,5791,479
Deferred revenue5,4971,206
Accrued expenses and other current liabilities69,48047,577
Total current liabilities127,80588,605
Operating lease liability, net of current portion2,4003,641
Long-term debt252,360202,834
Deferred revenue, non-current13,69913,699
Deferred royalty obligation related to the sale of future royalties27,21525,876
Total liabilities7423,4797334,655
Commitments and contingencies (Note 14)
Stockholders' equity
Common stock, $0.0001 par value per share; 500,000,000 shares authorized; 251,030,827 and 244,351,501 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively2524
Additional paid-in capital1,166,5061,113,666
Accumulated deficit(1,002,002)(946,939)
Accumulated other comprehensive (loss) income(483)198
Total stockholders' equity164,046166,949
Total liabilities and stockholders' equity$587,525$501,604

The accompanying notes are an integral part of these condensed financial statements.

ARDELYX, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS1

(Unaudited) (in thousands, except share and per share amounts)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues
Product sales, net4$125,455$105,515$336,957$263,406
Product supply revenue1,380—3,7106,439
Licensing revenue4216253635,065
Non-cash royalty revenue related to the sale of future royalties46044,7891,9757,195
Total revenues3127,6553110,329343,005282,105
Costs and operating expenses
Cost of sales4,5393,98215,10928,688
Research and development25,19918,06771,49048,671
Selling, general and administrative93,89483,612297,601250,822
Total costs and operating expenses123,632105,661384,200328,181
Income (loss) from operations4,0234,668(41,195)(46,076)
Interest expense(5,880)(5,796)(16,436)(14,343)
Non-cash interest expense related to the sale of future royalties(1,502)(2,188)(4,086)(6,478)
Other income, net2,7122,4496,8626,667
Loss before provision for income taxes(647)(867)(54,855)(60,230)
Provision for income taxes90102208962
Net loss5$(7375)$(969)$(55,063)$(61,192)
Net loss per share of common stock - basic and diluted$(0.00)$(0.00)$(0.22)$(0.25)
Shares used in computing net loss per share - basic and diluted250,007,187241,908,407247,991,715240,165,744
Comprehensive loss
Net loss$(737)$(969)$(55,063)$(61,192)
Unrealized (losses) gains on available-for-sale securities(290)162(681)67
Comprehensive loss$(1,027)$(807)$(55,744)$(61,125)

The accompanying notes are an integral part of these condensed financial statements.

ARDELYX, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY1

(Unaudited) (in thousands, except share amounts)
Three Months Ended September 30, 2026
Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other
Comprehensive Loss Total Stockholders' Equity
Shares Amount
Balance as of June 30, 2026249,147,061$25$1,150,446$(1,001,265)$(193)$149,013
Issuance of common stock under employee stock purchase plan214,774—690——690
Issuance of common stock upon exercise of options151,203—269——269
Issuance of common stock upon vesting of restricted stock units1,517,789—————
Stock-based compensation——15,101——15,101
Unrealized losses on available-for-sale securities————(290)(290)
Net loss———(737)—(737)
Balance as of September 30, 2026251,030,827$25$1,166,506$(1,002,002)$(483)$164,046

Nine Months Ended September 30, 2026

Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other

Comprehensive Income (Loss) Total Stockholders' Equity

Shares Amount

Balance as of December 31, 2025 244,351,501 $ 24 $ 1,113,666 $ ( 946,939 ) $ 198 $ 166,949 Issuance of common stock under employee stock purchase plan 351,254 — 1,432 — — 1,432 Issuance of common stock for services 32,627 — 185 — — 185 Issuance of common stock upon exercise of options 2,040,937 1 6,648 — — 6,649

Issuance of common stock upon vesting of restricted stock units 4,254,508 — — — — —

Stock-based compensation — — 44,575 — — 44,575

Unrealized losses on available-for-sale securities — — — — ( 681 ) ( 681 )

Net loss — — — ( 55,063 ) — ( 55,063 ) Balance as of September 30, 2026 251,030,827 $ 25 $ 1,166,506 $ ( 1,002,002 ) $ ( 483 ) $ 164,046

Table of Contents

Three Months Ended September 30, 2025
Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other
Comprehensive (Loss) Income Total Stockholders' Equity
Shares Amount
Balance as of June 30, 2025240,765,516$24$1,085,108$(945,563)$(38)$139,531
Issuance of common stock under employee stock purchase plan162,859—703——703
Issuance of common stock upon exercise of options860,811—2,111——2,111
Issuance of common stock upon vesting of restricted stock units1,182,652—————
Stock-based compensation——12,742——12,742
Unrealized gains on available-for-sale securities————162162
Net loss———(969)—(969)

Balance as of

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  2. CorMedix CRMD public float $910M, Jun 30, 2025
  3. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  4. Akebia Therapeutics AKBA public float $946M, Jun 30, 2025
  5. Neogen NEOG public float $972M, Nov 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.